AstraZeneca Pharma India Limited (BOM:506820)
6,387.90
+93.00 (1.48%)
At close: Nov 6, 2026
AstraZeneca Pharma India Revenue
AstraZeneca Pharma India had revenue of 7.44B INR in the quarter ending September 30, 2026, with 33.11% growth. This brings the company's total for the last twelve months to 26.09B, up 30.05% year-over-year. In the fiscal year ending March 31, 2026, AstraZeneca Pharma India had annual revenue of 22.76B with 32.59% growth. That makes AstraZeneca Pharma India the 15,633rd largest company in the world by revenue and 816th in India.
Revenue (ttm)
26.09B
Revenue Growth
+30.05%
P/S Ratio
6.12
Revenue / Employee
34.33M
Employees
600
Market Cap
159.70B
Revenue by Geography
- India 21.58B 94.8%
- Outside India 1.18B 5.2%
Fiscal year ended Mar 31, 2026 See the full AstraZeneca Pharma India breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 22.76B | 5.59B | 32.59% |
| Mar 31, 2025 | 17.16B | 4.21B | 32.48% |
| Mar 31, 2024 | 12.96B | 2.93B | 29.17% |
| Mar 31, 2023 | 10.03B | 1.97B | 24.50% |
| Mar 31, 2022 | 8.06B | -79.60M | -0.98% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jubilant Pharmova | 86.08B |
| Granules India | 58.93B |
| GlaxoSmithKline Pharmaceuticals | 41.98B |
| J. B. Chemicals & Pharmaceuticals | 41.48B |
| Viyash Scientific | 35.75B |
| FDC Limited | 22.89B |
| Caplin Point Laboratories | 22.87B |
| Morepen Laboratories | 22.86B |
AstraZeneca Pharma India News
- 1 day ago - AstraZeneca Pharma India Quarterly report: Q2 2027 - Filings
- 2 months ago - AstraZeneca Pharma India Quarterly report: Q1 2027 - Filings
- 4 months ago - AstraZeneca Pharma India appoints Mihir Parikh and Amay Ashok Pandey to key director roles - Business Upturn
- 4 months ago - AstraZeneca Pharma India appoints Praveen K Mittal as Director - Corporate Affairs - Business Upturn
- 4 months ago - AstraZeneca Pharma India announces resignation of senior management personnel - Business Upturn
- 4 months ago - AstraZeneca gets CDSCO approval to sell Enhertu in India for first-line HER2-positive breast cancer treatment - Business Upturn
- 5 months ago - Why are AstraZeneca Pharma shares down over 4% today? Explained - Business Upturn
- 5 months ago - AstraZeneca Pharma India Quarterly report: Q4 2026 - Filings